Clinical Trials Browser

Phase 1/2 × OTHER × silmitasertib × Clear all

NCT06541262 2026-03-02

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Phase 1/2 Recruiting

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma